Rolf Barth to Alemtuzumab
This is a "connection" page, showing publications Rolf Barth has written about Alemtuzumab.
Connection Strength
0.767
-
Alemtuzumab induction and belatacept maintenance in marginal pathology renal allografts. Clin Transplant. 2019 06; 33(6):e13531.
Score: 0.656
-
Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. Transpl Int. 2006 Nov; 19(11):885-92.
Score: 0.069
-
Comparison of Alemtuzumab Versus Basiliximab Induction Therapy in Elderly Kidney Transplant Recipients: A Single-Center Experience. J Pharm Pract. 2021 Apr; 34(2):199-206.
Score: 0.042